Sarepta Therapeutics (SRPT) Receivables - Other (2015 - 2026)

Sarepta Therapeutics' Receivables - Other history runs 16 years deep, the most recent figure standing at $136.4 million for Q1 2026.

• In Q1 2026, Receivables - Other rose 147.1% year-over-year to $136.4 million; the TTM figure through Mar 2026 stood at $136.4 million (up 147.1% YoY), while the FY2025 annual figure was $104.1 million, up 200.87% from the prior year.
• Receivables - Other for Q1 2026 stood at $136.4 million, up from $104.1 million in the prior quarter.
• The five-year high for Receivables - Other was $136.4 million in Q1 2026, with the low at $3.3 million in Q4 2022.
• The 5-year median for Receivables - Other is $34.6 million (2024), against an average of $51.4 million.
• The sharpest annual moves came in 2022 and 2024: Receivables - Other surged 41287.5% in 2022, then slumped 51.45% in 2024.
• Sarepta Therapeutics' Receivables - Other stood at $3.3 million in 2022, then jumped by 800.03% to $29.8 million in 2023, then rose by 16.11% to $34.6 million in 2024, then soared by 200.87% to $104.1 million in 2025, then jumped by 31.03% to $136.4 million in 2026.
• Business Quant data shows SRPT's Receivables - Other at $136.4 million in Q1 2026, $104.1 million in Q4 2025, and $128.7 million in Q3 2025.